Marketing analysis of the Russian pharmaceutical market for treatment of neovascular age-related macular degeneration; Маркетинговый анализ российского рынка лекарственных препаратов для терапии неоваскулярной возрастной макулярной дегенерации

Background. Studies on the pharmaceutical provision of neovascular age-related macular degeneration with angiogenesis inhibitors in the Russian Federation have repeatedly indicated a mismatch between the level of consumption and the actual need for these drugs. This highlights the importance of further research on the issue through marketing analysis. Objective: To conduct a marketing analysis of the market for angiogenesis inhibitors used in the treatment of neovascular age-related macular degeneration, including assessment of the product range, price dynamics, demand and consumption, as well as index analysis for the period of 2018–2024. Material and methods. The study was based on open data on the procurement of angiogenesis inhibitors in the public sector, price characteristics, and information on consumption with compulsory health insurance system (24-hour and day hospitals as well as high-tech medical care). The scientific and methodological framework of the study included methods for analyzing the sales of drugs from the group of angiogenesis inhibitors registered for medical use in the Russian Federation, as well as methodological tools for calculating a series of chain indices (including the weighted average price index, price index, structural shift index, index of changes in sales volumes in physical terms, modified Herfindahl–Hirschman index). Methods for analyzing the life cycle of the drugs and comparing the volumes of their procurement and consumption volumes were also used. Results. During the study period, there was a noticeable increase in the demand for and consumption of angiogenesis inhibitors: procurement volumes in physical terms grew 2.53-fold, and in monetary terms 1.62-fold. The positive dynamics of the market for the studied group of drugs were accompanied by an increase in weighted average prices and a growing share of more expensive drugs in the procurement structure. Between 2021 and 2023, uneven growth was observed in procurement volumes in physical terms and in the number of hospitalizations involving the use of these drugs. The ratio of hospitalization volumes to procurement volumes during this period was 1.21, 1.46, and 1.47, respectively, indicating that a single vial of the drug was used for multiple patients. The disproportion between procurement volumes and the number of hospitalizations points to a significant additional potential demand for angiogenesis inhibitors. The current market conditions can be characterized as attractive for manufacturers and suppliers. Conclusion. It was established that the market for angiogenesis inhibitors was characterized by both qualitative and quantitative growth, with sustained positive development dynamics. The identified features of procurement and consumption indicate the need for further research aimed at developing optimal solutions for ensuring the pharmaceutical provision of angiogenesis inhibitors to consumers in the required range and sufficient volumes. © 2025 Elsevier B.V., All rights reserved.